Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as a intravenous formulation for intravenous use. It treats metastatic colorectal cancer and other solid tumors in adult patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan Accord is a topoisomerase I inhibitor used in the management of solid tumours, particularly colorectal cancer.

Metastatic colorectal cancer: improves overall survival in adult patients. Advanced colorectal cancer: used in combination regimens to control disease progression. Other solid tumours (off‑label): may be considered in selected cases under specialist supervision.

Irinotecan Accord may cause a range of adverse reactions.

Common Side Effects: - Diarrhea - Neutropenia - Nausea and vomiting - Fatigue

Serious or Rare Side Effects: - Febrile neutropenia - Severe colitis or intestinal perforation - Allergic reactions (including anaphylaxis)

When using Irinotecan Accord, clinicians should observe several safety measures.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: evaluate hepatic enzymes before and during therapy. Hydration: ensure adequate fluid intake to mitigate diarrhoea. Pregnancy: avoid use unless benefits outweigh potential risks. Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan may interact with several medicines; awareness helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise irinotecan exposure. - Concurrent high‑dose anticoagulants (e.g., warfarin): may increase bleeding risk. - Live bacterial or viral vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce drug effectiveness. - Serotonin‑modulating antiemetics (e.g., ondansetron): may require dose adjustment.